Kraig Biocraft Laboratories Shares Update on Dragon Silk Production Utilizing the BAM-1 Platform

Rhea-AI Summary

Kraig Biocraft Laboratories (OTCQB: KBLB) has announced significant advancements in the commercialization of its BAM-1 recombinant spider silk production hybrids, first introduced in February 2024. The BAM-1 platform has proven to be the most resilient and efficient system for large-scale spider silk production. This technology has successfully integrated the desirable properties of spider silk into production-ready silkworm strains, resulting in the advanced Dragon SilkTM. CEO Kim Thompson emphasized the scalability and reliability of the BAM-1 hybrids in accelerating the market transition of spider silk technologies. Following successful spring production trials, the company is ahead of its 2024 production schedule and plans to expand production further in the coming weeks.

Positive

• The BAM-1 platform is the most robust and resilient system for commercial-scale spider silk production.
• Successfully concluded spring production trials with the BAM-1 hybrids.
• The BAM-1 hybrids feature a strong commercial genetic backbone.
• Integration of BAM-1 with Dragon SilkTM improves production capacity and efficiency.
• Kraig Labs is ahead of its 2024 production schedule.
• The company plans to provide further details on production expansion soon.

Negative

• No specific financial data or revenue projections were disclosed.
• No details on potential risks or challenges associated with the new production system were provided.

Ann Arbor, Michigan--(Newsfile Corp. - May 28, 2024) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs") announces an update on the commercialization of its BAM-1 recombinant spider silk production hybrids.

First made public in February of 2024, as part of the Company's now successfully concluded spring production trails, the BAM-1 hybrid is the latest development in recombinant spider silk production technology.

Kraig Labs' BAM-1 production platform has proven to be the most robust and resilient production system for commercial-scale production of recombinant spider silk. What sets the BAM-1 system apart from previous developments is the strong and robust commercial genetic backbone that these strains were developed into.

The BAM-1 hybrid system represents a major advancement in the production capacity for the Company's spider silk commercialization efforts. This new production platform integrates the Company's spider silk technologies into production-ready silkworm strains.

BAM-1 is a silk production system developed by Kraig Labs to serve as an integration platform for its recombinant spider silk technologies. The BAM-1 hybrids produce Dragon Silk^TM, one of the Company's major recombinant spider silk technology breakthroughs. Kraig Labs developed Dragon Silk to blend spider silk's incredible physical and chemical properties with commercially scalable technology leveraging mundane silk production infrastructure.

The Company's merger of the BAM-1 hybrid manufacturing technologies with the cutting-edge bio-engineering of Dragon Silk has created what Kraig Labs believes to be the most advanced and scalable spider silk production system in existence.

"The BAM-1 hybrids have been a huge success, and they are unlocking the powerful potential of our spider silk technologies," said Kim Thompson, Founder and CEO of Kraig Labs. "The BAM-1 hybrids have proven to be a scalable and reliable platform for Dragon Silk manufacturing. As we bring the next generation of pure spider silk technologies to market, the BAM-1 production system will serve to rapidly accelerate their transition to commercialization."

Due to the success of its spring production trials, the Company remains ahead of schedule for its 2024 production season. It expects to provide further details of that production expansion in the coming weeks.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210619

FAQ

What is Kraig Biocraft Laboratories' BAM-1 platform?

The BAM-1 platform is Kraig Biocraft Laboratories' advanced system for producing recombinant spider silk using genetically engineered silkworms. It is designed to be robust and scalable for commercial use.

What are the benefits of Kraig Biocraft Laboratories' BAM-1 hybrids?

The BAM-1 hybrids provide a reliable and scalable platform for producing Dragon SilkTM, blending spider silk's properties with scalable technology.

How has Kraig Biocraft Laboratories' BAM-1 platform performed in production trials?

The BAM-1 platform successfully completed spring production trials, demonstrating robustness and efficiency in large-scale spider silk production.

What is Kraig Biocraft Laboratories' Dragon SilkTM?

Dragon SilkTM is a breakthrough recombinant spider silk developed by Kraig Biocraft Laboratories, combining spider silk's physical and chemical properties with commercial scalability.

What are Kraig Biocraft Laboratories' plans for expanding BAM-1 production?

Following successful spring trials, Kraig Biocraft Laboratories plans to expand BAM-1 production and will provide further details in the coming weeks.

What is the stock symbol for Kraig Biocraft Laboratories?

The stock symbol for Kraig Biocraft Laboratories is KBLB.

When was the BAM-1 platform first introduced?

The BAM-1 platform was first introduced in February 2024.

Who is the CEO of Kraig Biocraft Laboratories?

Kim Thompson is the CEO of Kraig Biocraft Laboratories.

How does BAM-1 improve the production of spider silk?

BAM-1 integrates spider silk technology into production-ready silkworm strains, making the production process more scalable and efficient.

What is the significance of Kraig Biocraft Laboratories' BAM-1 platform for the textile industry?

The BAM-1 platform represents a major advancement in spider silk production, potentially revolutionizing the global textile industry with its scalable and robust production capabilities.